> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA OKs Production at Kite CAR T-Cell Facility
- URL: https://www.fdaweb.com/fda-oks-production-at-kite-car-t-cell-facility/
- Published: 2022-04-21T12:00:00.000Z
- Updated: 2026-09-14T17:41:41.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151647

FDA has approved commercial production at the new Kite CAR T-cell therapy manufacturing facility in Frederick, MD. Kite is a Gilead subsidiary. The site will produce Kite’s FDA-approved CAR T-cell therapy used to treat blood cancer, a company [statement](https://www.gilead.com/news-and-press/press-room/press-releases/2022/4/kite-receives-us-fda-approval-of-new-stateoftheart-car-tcell-therapy-manufacturing-facility-in-maryland?ref=fdaweb.com) says.

The statement says CAR T-cell therapies are individually manufactured for each patient using T-cells extracted from their white blood cells. A patient’s T-cells are sent to Kite’s manufacturing facilities where they are modified with a chimeric antigen receptor (CAR) to recognize, attack, and destroy their cancer cells.

Kite says that unlike most cancer treatments, CAR T-cell therapy is a one-time treatment that is available through authorized treatment centers or hospitals that have experience with such therapy.